国际眼科纵览 ›› 2021, Vol. 45 ›› Issue (5): 380-385.doi: 10.3760/cma.j.issn.1673-5803.2021.05.003

• 综述 • 上一篇    下一篇

眼表鳞状细胞瘤局部药物治疗进展

李涵灵  赵志远  张慧   

  1. 昆明医科大学第一附属医院眼科 650000
  • 收稿日期:2021-02-01 出版日期:2021-10-22 发布日期:2021-10-25
  • 通讯作者: 张慧,Email: huizh99@yahoo.com
  • 基金资助:
     国家自然科学基金(81560159);昆明医科大学2020年研究生创新基金项目(2020S134)

Progress of topical pharmacotherapy for ocular surface squamous neoplasia

i Hanling, Zhao Zhiyuan, Zhang Hui   

  1. Department of Ophthalmology, the Fist Affiliated Hospital of Kunming Medical University, Kunming 650000, China
  • Received:2021-02-01 Online:2021-10-22 Published:2021-10-25
  • Contact: Zhang Hui, Email: huizh99@yahoo.com
  • Supported by:
    National Natural Science Foundation of China (81560159); 2020 Postgraduate Innovation Fund Project of Kunming Medical University (2020S134)  

摘要: 眼表鳞状细胞瘤(ocular surface squamous neoplasia,OSSN)是眼科常见的眼表肿瘤,眼局部药物治疗具有非侵入性、创伤小的优点,有逐渐取代手术切除成为其首选治疗方式的趋势。目前局部药物除采用抗代谢、抗肿瘤、免疫调节作用的药物(丝裂霉素C、5-氟尿嘧啶、干扰素 α2b、维甲酸等)外,一些抗肿瘤血管及病因治疗的药物(抗血管内皮生长因子类药物、西多福韦等)也被用于OSSN临床治疗研究中。(国际眼科纵览,2020, 45: 380-386)

关键词: 眼表鳞状细胞瘤, 局部药物治疗, 非手术治疗 

Abstract: Ocular surface squamous neoplasia(OSSN) is the most common ocular surface tumor. Topical pharmacotherapy, a non-invasive and less surgical trauma, has become the first way in the treatment of OSSN. At present, in addition to the chemotherapeutic drugs (such as mitomycin C, 5-fluorouracil, interferon α2b, retinoic acid)with anti-metabolic, anti-tumor and immunomodulatory effects, other antiangiogenic therapy and etiological treatment (such as anti- vascular endothelial growth factor, cidofovir) have also been used in the clinical treatment of OSSN.  (Int Rev Ophthalmol, 2020, 45: 380-386)

Key words: ocular surface squamous neoplasia, topical pharmacotherapy, non-operative treatment